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Abstract
Earlier findings show seasonality in processes and behaviors such as brain plasticity and depression that in part are
regulated by Brain-Derived Neurotrophic Factor (BDNF). Based on this we investigated seasonal variation in serum BDNF
concentrations in 2,851 persons who took part in the Netherlands Study of Depression and Anxiety (NESDA). Analyses by
month of sampling (monthly n’s .196) showed pronounced seasonal variation in serum BDNF concentrations (P,.0001)
with increasing concentrations in the spring-summer period (standardized regression weight (ß) = 0.19, P,.0001) and
decreasing concentrations in the autumn-winter period (ß =20.17, P,.0001). Effect sizes [Cohen’s d] ranged from 0.27 to
0.66 for monthly significant differences. We found similar seasonal variation for both sexes and for persons with a DSM-IV
depression diagnosis and healthy control subjects. In explorative analyses we found that the number of sunshine hours (a
major trigger to entrain seasonality) in the week of blood withdrawal and the 10 weeks prior to this event positively
correlated with serum BDNF concentrations (Pearson’s correlation coefficients ranged: 0.05 – 0.18) and this could partly
explain the observed monthly variation. These results provide strong evidence that serum BDNF concentrations
systematically vary over the year. This finding is important for our understanding of those factors that regulate BDNF
expression and may provide novel avenues to understand seasonal dependent changes in behavior and illness such as
depression. Finally, the findings reported here should be taken into account when designing and interpreting studies on
BDNF.
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Introduction
The yearly orbit of the Earth around the Sun causes variability
in the length of day. Many species are sensitive to this and exhibit
biochemical and behavioral alternations as response. This has
been termed seasonality [1].
Seasonality has become engrained in the field of psychiatry and
clinical psychology through findings such as spring peaks in suicide
rates [2] and seasonal affective disorder [3,4]. Above this, subtle
effects of season on depressive behaviors have been described. For
instance, in periods in which there is relatively little daylight
otherwise healthy individuals show reduced levels of activity, less
interest in sex, and an increased urge for sleep [5,6]. Research at
the pre-clinical level confirmed these findings by showing similar
seasonal patterns in depressive-like behavior in rodents [7–9] and,
in addition, in brain plasticity [10,11] that has been linked to the
human depressed state [12]. Taken together, these findings suggest
that depressive behavior and related processes are sensitive to
natural occurring environmental cues such as the length of the
day.
Although the underlying mechanisms of seasonality in depres-
sive behaviors could not be elucidated yet, some data point to
variation in serotonin (5-hydroxytryptamine; 5-HT) expression as
being the molecular mechanism that thrives this association
[13,14]. Indeed, human studies show that central and peripheral
5-HT activity undergoes marked seasonal rhythmicity [13–19].
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Furthermore, 5-HT activity is positively related to the number of
ambient sunshine hours [13]. However, although linked to
depression, it has become increasingly clear that 5-HT alternations
are not sufficient to cause the primary depressive phenotype [20–
22]. So, seasonality in depressive behaviors might depend on
changes in a pathway down-stream of 5-HT rather than directly
through 5-HT signaling. Brain-Derived Neurotrophic Factor
(BDNF) could serve as a component in such a pathway. BDNF
is a signaling molecule that has a repertoire of regulatory functions
on a related set of phenomena that are (partly) seasonal (e.g.,
energy balance and brain plasticity [23–25]). It is well established
that 5-HT and BDNF interact with each other and it has been
suggested that these factors together have regulatory functions in
neuronal functioning and neuronal plasticity [26,27]. Further-
more, the intertwined relationship between 5-HT and BDNF plays
a fundamental role in the ‘neurotrophin hypothesis of depression’ [28].
This hypothesis has become a leading model in the field of
depression research by conceptualizing depressive disorders as
being partly the consequence of deficiencies in mechanisms related
to neuronal plasticity. Furthermore, the neurotrophin hypothesis
predicts that BDNF and its receptor Tyrosine kinase factor B
(TrkB) are targets of antidepressants because these factors
modulate neuroadaptive changes that are believed to be essential
for therapeutic change [12,20,28].
Given seasonality in 5-HT dynamics, the intrinsic relation
between 5-HT and BDNF, and links between BDNF and
processes and behaviors that occur according to a seasonal
pattern, serum BDNF concentrations may also follow a seasonal
pattern. A line of experimental work that has shown that light
deprivation reduces BDNF mRNA and protein expression in the
rat brain [29,30] also gives ground to this idea. To date, however,
no studies investigated seasonality in any BDNF parameter.
Clarifying this issue is important in understanding the factors that
influence BDNF expression, essential in evaluating research
findings, and maybe helpful for a better understanding of seasonal
variation in depressive-like behavior. Accordingly, we investigated
seasonality in serum BDNF concentrations that are assumed to
reflect central levels of BDNF [31,32]. Since seasonality is
entrained by environmental cues such as the number of sunshine
hours, we also explored the relation between serum BDNF
concentrations and this variable. Here we hypothesized that
BDNF concentrations will be positively related to the number of
sunlight hours, as has been shown for 5-HT expression [13].
Materials and Methods
Ethics Statement
Ethical approval for the study was obtained from the Ethical
Committees of the participating Institutes and all subjects gave
their written informed consent.
Subjects
Subjects were derived from the baseline sample of the
Netherlands Study of Depression and Anxiety (NESDA). The
NESDA is an ongoing cohort study among 2,981 persons who
were recruited in mental health care, primary care and in the
general population. Included in the NESDA were persons with a
depressive and/or an anxiety disorder, persons with a depressive
and/or an anxiety disorder in remission and persons without
lifetime depressive or anxiety disorders. Exclusion criteria were
evidence for psychotic-, bipolar I- or II-, or obsessive-compulsive
disorder, severe alcohol use, and not being fluent in Dutch (see
Ref. [33] for full details). For our present purposes, subjects were
eligible on whom data on serum BDNF concentrations and date of
blood withdrawal were available (N= 2,851, not eligible n = 130
[,4.5%]). Eligible and not-eligible persons did not differ with
regard to gender, age and psychiatric diagnoses (all P values..25).
Demographical, Behavioral, and Clinical Measurements
Basic demographic and behavioral information on the sample
(e.g., Body Mass Index (BMI measured: weight/height2), alcohol
use, and time of blood withdrawal) was acquired through standard
questions and procedures [33]. Information on the amount of
physical activity the participants engaged in was acquired by
means of the International physical activity questionnaire and
expressed as the number of met-minutes (i.e., the ratio of the
amount of energy expenditure during activity to the energy
expenditure at rest) [34]. Smoking was dichotomized in current
smoker versus non-current smoker and alcohol use as abstainer
versus non-abstainer.
Trained staff administered the reliable and valid Composite
International Diagnostic Interview version 2.1 (CIDI) [35] to
establish lifetime and current (i.e., a diagnoses in the past 6-
months) psychiatric diagnoses (Diagnostic and Statistical Manual
of Mental Disorders, fourth edition (DSM-IV) [36]. The severity of
depressive and anxiety symptoms was assessed using the Inventory
of Depressive Symptoms (IDS) [37] and Beck’s Anxiety Inventory
(BAI) [38]. The use of pharmacological antidepressants (i.e.,
selective serotonin reuptake inhibitors, serotonin-norepinephrine
reuptake inhibitors, trycyclic antidepressants, noradrenergic and
specific serotonergic antidepressants, and ST John’s wort) was
assessed by means of self-report and drug container observation.
Antidepressant use was dichotomized in yes versus no use, with use
defined as intake of minimally the daily dose as recommended by
the World Health Organization (WHO) [39] on.50% of the days
during the last month.
BDNF Measurements
Fifty ml of venous blood was withdrawn into vacuum tubes
between 07:30 and 09:30 a.m. after an overnight fast (from August
2004 to March 2007). Serum was separated immediately and
stored (at 285uC) until assay. Serum BDNF concentrations were
determined, in a laboratory of the University of Maastricht, the
Netherlands, using the Emax Immuno Assay system from
Promega according to the manufacturer’s protocol (Madison,
WI, USA). Absorbency was read in duplicate using a Bio-Rad
Benchmark microplate reader (Hercules, CA, USA) at 450 nm.
Serum BDNF concentrations were expressed as ng/ml. The
coefficients of variance ranged between 2.9% and 8.1%. Further
information on the exact procedures that were used and the
validity and reliability of the measurements is provided elsewhere
[40].
Sunlight Measurements
The number of sunlight hours was measured using pyran-
ometers (World Meteorological Association (WMO) [41], on a
daily basis, at weather stations of the Dutch Royal Meteorological
Institute (KNMI; www.knmi.nl). The weekly number of sunlight
hours was defined as the sum of all sub-periods in that week for
which the solar irradiance exceeded 120 W/m2. Since NESDA
gathered data at multiple sites in the Netherlands (i.e., the
Amsterdam, Groningen, and Leiden) data on the number of
sunlight hours were collected from the weather stations that were
most nearby the study sites (i.e., Schiphol weather station [latitude:
52u189N] for the Amsterdam and Leiden areas [approximate
latitudes: 52u319N and 52u099N respectively] and Eelde weather
station [latitude: 53u089N] for the Groningen area [approximate
latitude: 53u129N]).
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Statistical Analyses
Data were analyzed in SPSS 18.0 (Chicago, IL, USA) and are
presented as the average 6 standard deviation, unless otherwise
indicated. Seasonal and monthly differences in demographical,
behavioral, and clinical variables were analyzed using a Chi-
square (categorical variables) or Fisher’s exact test (continuous
variables). Statistical significance was set at P,.05 (two-tailed).
Effect sizes were reported as standardized Cohen’s d [42],
standardized regression weights (ß), or eta-squared (g2) where
appropriate.
Analysis of covariance (ANCOVA) was used to test for
differences in serum BDNF concentrations by calendar month of
sampling. The following covariates were included in the analysis:
gender, ethnicity, age, BMI, time of the day of blood draw,
duration of serum storage, a current depression and/or anxiety
diagnosis, antidepressant use, and sampling site because these
variables have been shown to affect serum BDNF concentrations
[40,43]. The ANCOVA was followed up by Bonferroni corrected
post-hoc tests when required. In view of earlier findings [40,43],
three additional sub-group analyses were performed with gender,
psychiatric status, and antidepressant treatment status as addi-
tional grouping factors in order to assess potential interaction
effects between these variables and month of sampling. In a similar
manner we tested whether the earlier reported lower BDNF
concentrations in antidepressant free depressed persons as
compared to healthy control subjects, remitted depressed persons,
and antidepressant treated depressed persons [43] remained
statistically significant when month of sampling was controlled for.
Associations between the number of sunshine hours in the week
of blood withdrawal and serum BDNF concentrations were
explored using zero-order and partial Pearson’s product-moment
correlation coefficients (r). For the latter, the variance due to the set
of covariates (see above) was taken into account. We anticipated
that sunlight related BDNF alternations could occur with some
time delay and therefore we not only related BDNF concentrations
to the number of sunshine hours in the week of blood withdrawal,
but also to the number of sunshine hours in the 10 weeks prior to
blood withdrawal separately. Finally, the variables coding for the
number of sunshine hours in the week of blood withdrawal and the
10 weeks prior to this event, were entered together in 1 block of a
multiple stepwise regression analysis (the set of covariates was
entered in a first block) to test the cumulative effect of the number
of sunshine hours in the recent past on serum BDNF concentra-
tions.
Results
The overall sample (N= 2,851) had a mean age of 41.8613.1
years and included 1,827 women (66.5%). Table 1 shows the
characteristics of the study participants by season of sampling
(Table S1 shows the characteristics of the study participants by
month of sampling). Subtle seasonal differences were observed in
measures for psychiatric diagnoses and depression severity. These
differences were similar to the findings reported by Winthorst and
colleagues [44] who studied seasonal variation of depressive and
anxiety symptoms using, in part, the same data. Shortly, there was
a small rise in the winter season in the percentage of clinical
diagnoses of depression and depression-anxiety and related to this,
on average higher scores on the IDS and a slightly higher number
of persons who used an antidepressant. Next to this, persons who
were sampled in the winter tended to have a somewhat higher
BMI (all differences ,1 BMI point) as compared to persons who
were sampled in the other seasons.
Seasonality in Serum BDNF Concentrations
Using ANCOVA we found strong indications for a seasonal
pattern in serum BDNF concentrations (overall F= 11.32,
P,.0001, g2 = 0.04, see Figure 1). This seasonal pattern was such
that serum BDNF concentrations were, on average, lower in the
months January to May and higher in the months June to
December. Pair-wise comparisons by month of sampling are given
in Table S2. Effect sizes for monthly differences that were
statistically significant after Bonferroni corrections ranged from
small (d = 0.27, January versus August) to large (d = 0.66, March
versus September). Results from separate ANCOVA’s showed a
similar seasonal pattern in serum BDNF concentrations for males
and females (see Figure 2, panel A), depressed and non-depressed
persons (see Figure 2, panel B), and for antidepressant treated (any
antidepressant) and antidepressant free persons (data not shown). P
values for the interaction terms between these additional grouping
factors and month of sampling were all ..10. Given our earlier
findings showing that serum BDNF concentrations were highest in
currently depressed persons on selective serotonin reuptake
inhibitors or ST John’s wort [43] we in addition tested for
seasonality in serum BDNF concentrations in persons using these
agents. Here, a similar seasonal effect in serum BDNF concen-
trations was observed (g2 = 0.074).
Nadir (March) and peak (September) BDNF concentrations
showed a correspondence with the end of the Dutch winter and
the end of the Dutch summer respectively. Even more, the pattern
of BDNF concentrations over the year suggested an increase
during the Dutch spring-summer period (equinox vernal, March
20 to September 22) and a decrease in the Dutch autumn-winter
period (equinox autumnal, September 23 to March 19). Indeed,
when decomposed by equinox, we observed a coherent pattern of
increasing BDNF concentrations during the spring and summer
(n = 1,356, ß = 0.19, P,.0001) and decreasing BDNF concentra-
tions during the autumn and winter (n = 1,495, ß =20.17,
P,.0001; see Figure S1; t = 9.87 (P,.0001) for the interaction
equinox of sampling - consecutive week of sampling within the
equinox).
Although somewhat attenuated, the earlier reported main
effects [43] of lower serum BDNF concentrations in antidepressant
free depressed persons as compared to healthy control subjects,
remitted depressed persons, and antidepressant treated depressed
persons [43] remained statistically significant (P= .04, P,.001,
and P= .04 respectively) in analyses in which these factors coding
for diagnostic and treatment status were added as grouping factors
next to month of sampling.
Explorative Analyses: Sunshine Hours and Serum BDNF
Concentrations
The number of sunshine hours per week throughout the year
ranged from 2 hours per week to 131 hours per week. Exploratory
analyses showed small positive correlations between the number of
sunshine hours (in the week of blood withdrawal, and the 10 weeks
prior to that) and serum BDNF concentrations ([zero order and
partial] in the range: r=0.04 – r=0.18; see Table S3 and Figure
S2). Correlations were largest for the number of sunlight hours 7
and 8 weeks prior to blood withdrawal. Together, the number of
weekly sunlight hours in the week of sampling and in the 10 weeks
prior to the week of sampling, positively predicted serum BDNF
concentrations (entered in 1 block of a multiple stepwise regression
analysis (the set of covariates was entered as a first block):
DF= 11.22, multiple correlation= 0.21, P,.0001). The number of
sunshine hours could partly explain the monthly differences in
serum BDNF concentrations (i.e., g2 = 0.041, P,.0001 before and
g2 = 0.011, P= .003 after the inclusion of the number of sunlight
Seasonality in Serum BDNF Concentrations
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hours as covariates in the ANCOVA). Additional explorative
analyses showed a similar pattern of correlations between the
length of the natural photoperiod in the week of blood withdrawal,
and the 10 weeks prior to that, and serum BDNF concentrations.
Discussion
The novel finding that emerges from this study is that of
pronounced seasonal variation in serum BDNF concentrations.
The seasonality that we observed followed a coherent pattern of
increasing BDNF concentrations over the course of the spring and
the summer and, conversely, decreasing BDNF concentrations
over the course of the autumn and the winter. Illustrative for the
robustness of our finding was that the seasonal pattern was similar
for both sexes and for conditions in which BNDF expression is
altered, such as a diagnosis of major depression [45]. By means of
covariate adjusted analyses we could exclude a range of potentially
alternative explanations for our findings, including effects of for
example physical activity and BMI that have been reported to be
seasonal [46,47] and that have been linked to serum BDNF
concentrations as well [48,49]. In addition, our results were of a
relatively large magnitude with effect sizes (Cohen’s d) up to 0.66
for monthly differences. Together, these findings may have
significant implications as discussed below.
Seasonality in Serum BDNF Concentrations: Mechanisms
and Theoretical Implications
What might explain the strong pattern of seasonality in serum
BDNF concentrations? Differences in cAMP-response element
binding protein (CREB) activity could be an option. CREB is a
transcription factor that binds to the promoter region of the BDNF
gene and positively regulates BDNF transcription [50]. CREB
activity is under the influence of 5-HT. Given that long day
conditions give rise to a higher 5-HT expression [13], seasonality
Table 1. Descriptive information on the NESDA sample (mean 6 std or percentages [n]) by season of sampling.
Spring: Mar 21–Jun 20
(n=693)
Summer: Jun 21–Sept
20 (n=663)
Autumn: Sept 21–
Dec 20 (n=815)
Winter: Dec 21–
Mar 20 (n=680) P value
Females 67.3% [466] 65.0% [431] 65.2% [531] 67.9% [462] = .54
Age 41.5613.2 41.0613.3 42.5613.1 42.3612.5 = .08
Northern European ancestry 95.7% [663] 94.3% [625] 94.1% [766] 95.1% [647] = .49
Education (years) 12.363.3 12.263.3 12.163.3 12.063.2 = .40
Body Mass Index 25.364.5 25.765.1 25.365.1 26.165.3 ,.05 a
Smoker 37.3% [258] 34.6% [229] 34.2% [279] 33.2% [226] = .43
Physical activity 1 3.663.1 3.763.2 3.463.1 3.463.2 = .33
Time of blood draw 08:48617.4 08:47620.4 08:49633.3 08:59622.8 = .77
Psychiatric status
Healthy controls 2 43.9% [304] 45.2% [300] 47.1% [384] 36.7% [250] ,.001b
MDD 2 12.3% [85] 12.2% [81] 11.2% [91] 16.0% [108] ,.05a
Anxiety 2, 3 20.5% [142] 18.3% [121] 17.5% [143] 21.0% [143] = .23
Comorbid MDD-anxiety 2, 3 23.4% [162] 24.3% [161] 24.2% [197] 26.3% [179] = .63
Antidepressant medication 4 23.4% [162] 22.2% [147] 24.9% [203] 28.2% [192] = .05
Depression severity, IDS 21.2614.5 20.1614.5 20.9615.0 22.8613.9 ,.01a
Anxiety severity, BAI 12.1610.7 11.6610.5 12.0611.5 12.6610.5 = .52
Non-alcohol drinker 46.4% [322] 50.9% [337] 52.2% [425] 49.5% [337] = .21
Abbreviations: BAI, Beck’s Anxiety Inventory; IDS, Inventory of Depressive Symptoms; MDD, Major Depressive Disorder.
1 Mean met-minutes (i.e., ratio of energy expenditure during activity to energy expenditure at rest).
2 Current (6 months diagnosis).
3 Included a diagnosis of social phobia, panic disorder, generalized anxiety disorder, and/or agoraphobia.
4 Included the use of a pharmacological antidepressant (SSRI, SNRI, TCA, NaSSA, and/or St. John’s worth) for at.
least one month at regular dose (World Health Organization [WHO]).
a Post-hoc tests showed higher levels in the winter as compared to the other seasons.
b Post-hoc tests showed higher percentages in the summer, autumn and spring as compared to the winter season.
doi:10.1371/journal.pone.0048046.t001
Figure 1. Serum BDNF concentrations by month of sampling.
Error bars reflect the SEM. For pair-wise comparisons we refer to
Table S2.
doi:10.1371/journal.pone.0048046.g001
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in serum BDNF concentrations may be entrained by 5-HT
induced CREB activation. This explanation would fit with
observations that come from the field of antidepressant research.
For example, increases in the transcriptional activity of BDNF in
the course of treatment with a selective serotonin reuptake
inhibitor are often observed but these only occur in the face of
an increase in CREB activity [51]. Also, antidepressants give rise
to increased CREB activity but only if they are administered
chronically (e.g., $21 days) [51]. This appears to be in agreement
with our observation that the correlations between BDNF
concentrations and the number of sunshine hours were largest
for the number of sunshine hours in 7 to 8 weeks prior to blood
withdrawal. Furthermore, peak serum BDNF values were
observed in the early autumn and nadir values in the early spring.
So, the seasonality in BDNF expression seems to occur with a
time-delay relative to the seasons and their corresponding weather
characteristics.
Important for the interpretation of our results is the question
whether peripheral differences in serum BDNF concentrations
imply that there also are differences at the level of the Central
Nervous System (CNS). As already shortly mentioned in the
introduction part of our paper, it has been shown in rodents that
BDNF crosses the blood-brain barrier [31] and that peripheral
and central BDNF concentrations correlate positively in rodents
and in pigs [32]. Therefore it is reasonable to assume that blood
BDNF concentrations reflect BDNF concentrations in the CNS.
Unfortunately the literature on this topic in humans is limited to
only one study in which blood simultaneously was derived from
high up the jugular veins and arterial veins [52]. The results of this
study showed that BDNF levels were higher in blood that was
derived from the internal jugular veins as compared to arterial
blood. This indeed is indicative for CNS production of BDNF that
is obtained from peripheral tissues [52]. It should be noted though
that some studies report null-findings with regard to an association
between peripheral BDNF concentrations and more central
parameters for BDNF activity (e.g., the absence correlations
between plasma and cerebral spinal fluid concentrations of BDNF
[53]).
Seasonality in Serum BDNF Concentrations: Practical
Implications
Notwithstanding some uncertainty with regard to the exact
mechanisms underlying the seasonality in BDNF expression, our
findings have immediate and important practical implications.
First, our findings are of essential importance in the interpretation
of results from longitudinal studies. That is, the results of trials that
have serum BDNF concentrations as an outcome measure and
that span several months, might be of little use unless detailed
knowledge on seasonal effects is available. Second, and in
agreement with the latter statement, our results stress the need
to sample groups (e.g., depressed patients versus healthy control
subjects) equally over the year in order to gain credibility and
validity in research findings.
Strengths, Limitations, and Future Studies
Our study has strengths, notably reliability through a large
sample size and validity through the adjustment for a range of
confounders and the possibility to perform subgroup analyses.
However, there are also limitations. First, we used between-subject
data whereas within-subject data with repeated samplings
(monthly or more often) over at least 1 calendar year is more
appropriate to establish seasonality. Second, there must have been
some noise in the measurements related to the variables that coded
for the hours of sun in the weeks prior to blood withdrawal. That
is, we assigned each individual the number of sun hours that were
recorded in the particular region these persons lived in under the
assumption that they actually were in that particular region.
However, we do not know this with certainty (e.g., participants
may have been on vacation) and we also do not know whether
they truly were exposed to the sun (e.g., participants may have
stayed inside). We assume that this resulted in random noise that
decreased our ability to detect associations and thus that the true
associations between sunlight hours and serum BDNF concentra-
tions are likely to be of a larger magnitude than as reported here.
Also, from our data we can not conclude whether serum BDNF
concentrations are kept in a certain homeostatic range over the
year to serve a given function or whether we observed an
epiphenomenon of some other physiological or (unmeasured)
Figure 2. Serum BDNF concentrations by month of sampling and gender (Panel A) and current psychiatric status (Panel B). Error bars
reflect the SEM.
doi:10.1371/journal.pone.0048046.g002
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behavioral process that may be unrelated to central BDNF
functioning. Finally, a limitation with regard to the Promega
BDNF ELISA kit that was used in our study for serum BDNF
measurements is that it quantifies total amount of BDNF without
distinguishing between the pro- and the mature BDNF forms
[54,55]. It could well be that the percentage of mature BDNF to
total BDNF in serum may be altered as a function of seasonal
period. Only very recently it has been shown that such an
important distinction can be made [55,56] and thus future studies
could look into differences in pro-mature BDNF ratios over the
seasons.
For future studies it further would be interesting to elucidate
whether tryptophan, 5-HT, and/or CREB activity, truly have
important roles, as hypothesized here, in the chain of events that in
the end may lead to seasonality in serum BDNF concentrations. It
also would be particularly interesting to study BDNF concentra-
tions as a function of selected levels of (sun)light exposure. We
would expect that serum BDNF concentrations will vary less in
areas where the seasons, the number of sunlight hours, and/or the
natural length of day vary less over the year (e.g., closer to the
equator as compared to the Netherlands or 12 hours light/dark
regimens in laboratories). Finally, in the light of our findings that
serum BDNF concentrations are correlated with the amount of
ambient sunlight (and with the length of the photoperiod) an
important area of investigation would be to investigate changes in
serum BDNF concentrations in the course of treatment with bright
light [57] in conditions that have been associated with an altered
BDNF expression [30].
Summary and Conclusions
Here we demonstrate that serum BDNF concentrations
profoundly vary over the year and that this occurs according to
a coherent pattern of increasing BDNF concentrations in the
spring-summer period and decreasing BDNF concentrations in the
autumn-winter period. In addition we show correlations between
serum BDNF concentrations and the number of sunlight hours.
Although much remains to be understood with regard to these
associations and notwithstanding some limitations, we believe that
these results invite for a perspective on BDNF related mechanisms
in which seasonality is engrained.
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Figure S1 Mean normalized serum BDNF concentra-
tions plotted as a function of each consecutive week of
measurement in each equinox.
(TIF)
Figure S2 Partial Pearson’s correlation coefficients (for
covariates see the paper) on the relation between mean
serum BDNF concentrations and the hours of sunlight in
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